

October 16, 2023

Kidswell Bio Corporation

Code: 4584 (TSE Growth)

Shinya Kurebayashi, President & CEO

Announcement of enrollment of the first case of clinical research plan for children with cerebral palsy under the initiative of Nagoya University
(Excerpt from Japanese version)

Tokyo, October 16, 2023 – As an outcome of the clinical research which is laid out under the initiative of Nagoya University to examine the safety and tolerability of a single administration of autologous SHED (stem cells from human exfoliated deciduous teeth) for children with cerebral palsy, the first patient was enrolled on October 11, 2023. Kidswell Bio Corporation will continue to collaborate with Nagoya University to promote this clinical research.

For more information, please refer to the following website.

JRCT (Japan Registry of Clinical Trials)

<https://jrct.niph.go.jp/latest-detail/jRCTb040230042>

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which KWB has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children's potential vital force such as SHED, stem cell from exfoliated deciduous teeth, we envision creating new pharmaceuticals and therapeutics for all people under "Kids Well, All Well."

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com